COG-AHOD1331

A randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND # 117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Contact phone
517.364.5591
Principal investigator
Renuka Gera. MD
Trial Category
Childhood Cancers
Trial SubCategory
Lymphoma
Webform